Compare GameStop Corp. (GME) vs BIO-TECHNE Corp (TECH) Price & Performance

GameStop Corp.Trade

BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

GameStop Corp. vs BIO-TECHNE Corp — how do they compare? GameStop Corp. trades at $18.84 (market cap $8.44B), while BIO-TECHNE Corp trades at $71.9 (market cap $11.24B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals.

	GME	TECH
Market Cap	$8.44B	$11.24B
Sector	Consumer Cyclical	Health
52-Week High	$27.69	$72.29
52-Week Low	$18.79	$43.31
Enterprise Value	$4.42B	$11.32B
Dividend Yield	—	0.44%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GME

GameStop upgraded to 'Buy' as revenue, profits, and cash flow improve significantly in collectibles business.Seeking Alpha · 1 day agoBullish GameStop CEO may drop $56B eBay takeover bid, eyeing partnership insteadNew York Post · 1 day agoBearish GameStop may drop $56B eBay buy, opts for partnership to boost collectibles market.PYMNTS · 1 day agoNeutral View details →

TECH

Bio-Techne declares $0.08 quarterly dividend payable August 28, 2026.PRNewsWire · 4 hours agoBullish Bio-Techne reports flat FY2026 revenue, EPS rise, and confirms $11.3B acquisition by Merck KGaA.PRNewsWire · 4 hours agoBullish View details →

About GameStop Corp.

Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.